Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL IMMUNOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-04-14
DOI
10.1007/s10875-021-01036-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Better prognosis in females with severe COVID-19 pneumonia: possible role of inflammation as potential mediator
- (2021) Cristina Mussini et al. CLINICAL MICROBIOLOGY AND INFECTION
- Interferon-β Therapy in a Patient with Incontinentia Pigmenti and Autoantibodies against Type I IFNs Infected with SARS-CoV-2
- (2021) Paul Bastard et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Human inborn errors of immunity to herpes viruses
- (2020) Emmanuelle Jouanguy et al. CURRENT OPINION IN IMMUNOLOGY
- Autoantibodies against cytokines: phenocopies of primary immunodeficiencies?
- (2020) Chen-Lung Ku et al. HUMAN GENETICS
- Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
- (2020) Ivan Fan-Ngai Hung et al. LANCET
- COVID-19: consider cytokine storm syndromes and immunosuppression
- (2020) Puja Mehta et al. LANCET
- Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study
- (2020) Christopher M Petrilli et al. BMJ-British Medical Journal
- Type 1 interferons as a potential treatment against COVID-19
- (2020) Erwan Sallard et al. ANTIVIRAL RESEARCH
- Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy
- (2020) Giacomo Grasselli et al. JAMA Internal Medicine
- A systematic review and meta-analysis of published research data on COVID-19 infection-fatality rates
- (2020) Gideon Meyerowitz-Katz et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Inborn errors of type I IFN immunity in patients with life-threatening COVID-19
- (2020) Qian Zhang et al. SCIENCE
- Autoantibodies against type I IFNs in patients with life-threatening COVID-19
- (2020) Paul Bastard et al. SCIENCE
- Selection of an Optimal Combination Panel to Better Triage COVID-19 Hospitalized Patients
- (2020) Yueting Tang et al. Journal of Inflammation Research
- Elevated serum ferritin level effectively discriminates severity illness and liver injury of coronavirus disease 2019 pneumonia
- (2020) Peng Cao et al. BIOMARKERS
- Comorbidity and clinical factors associated with COVID-19 critical illness and mortality at a large public hospital in New York City in the early phase of the pandemic (March-April 2020)
- (2020) Thomas D. Filardo et al. PLoS One
- Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study
- (2020) Belén Ruiz-Antorán et al. Infectious Diseases and Therapy
- Decoding type I and III interferon signalling during viral infection
- (2019) Emily V. Mesev et al. Nature Microbiology
- Host genetics of severe influenza: from mouse Mx1 to human IRF7
- (2016) Michael J Ciancanelli et al. CURRENT OPINION IN IMMUNOLOGY
- Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus
- (2013) Jasper F.W. Chan et al. JOURNAL OF INFECTION
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support
- (2008) Paul A. Harris et al. JOURNAL OF BIOMEDICAL INFORMATICS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started